Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, is characterized
by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology
is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of
controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was
to evaluate the anti-inflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing
15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained
demonstrated that 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated
to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk
is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.
Keywords: Colitis, fermented milk, inflammation, lactic acid bacteria, Lactococcus lactis lipoxygenase.
Rights & PermissionsPrintExport